Bio-Connect
Immunohistochemical staining of formalin fixed and paraffin embedded human Hodgkins lymphoma tissue section using anti- CD30 rabbit monoclonal antibody (Clone RM425) at a 1:100 dilution.
Immunohistochemical staining of formalin fixed and paraffin embedded human Hodgkins lymphoma tissue section using anti- CD30 rabbit monoclonal antibody (Clone RM425) at a 1:100 dilution.
Immunohistochemical staining of formalin fixed and paraffin embedded human Hodgkins lymphoma tissue section using anti- CD30 rabbit monoclonal antibody (Clone RM425) at a 1:100 dilution.

anti-CD30 (human), Rabbit Monoclonal (RM425)

Research Use Only
REV-31-1312-00
RevMAb Biosciences
ApplicationsImmunoHistoChemistry, Western Blot
Product group Antibodies
ReactivityHuman
TargetTNFRSF8
Price on request
Packing Size
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    RevMAb Biosciences
  • Product Name
    anti-CD30 (human), Rabbit Monoclonal (RM425)
  • Delivery Days Customer
    5
  • Applications
    ImmunoHistoChemistry, Western Blot
  • Certification
    Research Use Only
  • Clonality
    Monoclonal
  • Clone ID
    RM425
  • Gene ID943
  • Target name
    TNFRSF8
  • Target description
    TNF receptor superfamily member 8
  • Target synonyms
    CD30; CD30L receptor; cytokine receptor CD30; D1S166E; Ki-1; Ki-1 antigen; lymphocyte activation antigen CD30; tumor necrosis factor receptor superfamily member 8
  • Host
    Rabbit
  • Isotype
    IgG
  • Scientific Description
    CD30 (Ki-1, TNF Receptor Superfamily Member 8) is a type I transmembrane glycoprotein of the TNF receptor superfamily. CD30 was originally identified as a cell surface antigen of Hodgkins and Reed-Sternberg cells using monoclonal antibody Ki-1. The ligand for CD30 is CD30L (CD153). The binding of CD30 to CD30L mediates pleiotropic effects including cell proliferation, activation, differentiation, and apoptotic cell death. CD30 has a critical role in the pathophysiology of Hodgkins disease and other CD30+ lymphomas. CD30 acts as a costimulatory molecule in thymic negative selection. In addition to its expression on Hodgkins and Reed-Sternberg cells, CD30 is also found in some non-Hodgkins lymphomas (including Burkitts lymphomas), virus-infected T and B cells, and on normal T and B cells after activation. In T cells, CD30 expression is present on a subset of T cells that produce Th2-type cytokines and on CD4+/CD8+ thymocytes that co-express CD45RO and the IL4 receptor. Soluble form of CD30 (sCD30) serves as a marker reflecting Th2 immune response. TRAF2 and TRAF5 can interact with this receptor, and mediate the signal transduction that leads to the activation of NF-kappaB. CD30 is a positive regulator of apoptosis, and has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity. Two alternatively spliced transcript variants of this gene encoding distinct isoforms have been reported. CD30 is expressed by mononuclear cells in Hodgkins lymphoma, Reed Sternberg cells and most Anaplastic Large Cell Lymphomas (ALCL). CD30 is also expressed by embryonal carcinomas. - Recombinant Antibody. This antibody RM425 reacts to human CD30. Application: IHC, WB . Source: Rabbit. Liquid. 50% Glycerol/PBS with 1% BSA and 0.09% sodium azide. CD30 (Ki-1, TNF Receptor Superfamily Member 8) is a type I transmembrane glycoprotein of the TNF receptor superfamily. CD30 was originally identified as a cell surface antigen of Hodgkins and Reed-Sternberg cells using monoclonal antibody Ki-1. The ligand for CD30 is CD30L (CD153). The binding of CD30 to CD30L mediates pleiotropic effects including cell proliferation, activation, differentiation, and apoptotic cell death. CD30 has a critical role in the pathophysiology of Hodgkins disease and other CD30+ lymphomas. CD30 acts as a costimulatory molecule in thymic negative selection. In addition to its expression on Hodgkins and Reed-Sternberg cells, CD30 is also found in some non-Hodgkins lymphomas (including Burkitts lymphomas), virus-infected T and B cells, and on normal T and B cells after activation. In T cells, CD30 expression is present on a subset of T cells that produce Th2-type cytokines and on CD4+/CD8+ thymocytes that co-express CD45RO and the IL4 receptor. Soluble form of CD30 (sCD30) serves as a marker reflecting Th2 immune response. TRAF2 and TRAF5 can interact with this receptor, and mediate the signal transduction that leads to the activation of NF-kappaB. CD30 is a positive regulator of apoptosis, and has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity. Two alternatively spliced transcript variants of this gene encoding distinct isoforms have been reported. CD30 is expressed by mononuclear cells in Hodgkins lymphoma, Reed Sternberg cells and most Anaplastic Large Cell Lymphomas (ALCL). CD30 is also expressed by embryonal carcinomas.
  • Reactivity
    Human
  • Storage Instruction
    -20°C
  • UNSPSC
    12352203